Previous close | 10,862.00 |
Open | 10,946.00 |
Bid | 10,906.00 x 0 |
Ask | 10,910.00 x 0 |
Day's range | 10,858.00 - 11,018.00 |
52-week range | 9,461.00 - 12,348.00 |
Volume | |
Avg. volume | 2,898,752 |
Market cap | 169.068B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 35.64 |
EPS (TTM) | 3.06 |
Earnings date | 25 Apr 2024 |
Forward dividend & yield | 2.28 (2.10%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | 125.32 |
Facing accusations of greed, the pay packages of FTSE CEOs are back in the headlines. But our writer takes a more relaxed view, on one condition. The post I don’t care how much FTSE bosses are paid as long as they make me rich! appeared first on The Motley Fool UK.
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).
The FDA approves AstraZeneca's (AZN) Fasenra as an add-on maintenance treatment for patients with severe asthma aged six to 11 years.